# OnCo record impact-sipuleucel-t (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/impact-sipuleucel-t/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "impact-sipuleucel-t", "NCT00065442" ;
  schema:name "IMPACT (sipuleucel-T)"@en ;
  schema:alternateName "IMPACT"@en, "D9902B"@en, "Immunotherapy for Prostate Adenocarcinoma Treatment"@en ;
  schema:description "The first cancer vaccine ever approved anywhere. It extended life by about four months without shrinking a single tumour, and the company that made it went bankrupt."@en ;
  schema:url <https://onco.cc/trials/impact-sipuleucel-t/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00065442>, <https://doi.org/10.1056/NEJMoa1001294>, <https://www.nice.org.uk/guidance/ta332> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/dendritic-cell-vaccines/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/sipuleucel-t/> ;
  onco:companies <https://onco.cc/companies/dendreon/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/> ;
  onco:trials <https://onco.cc/trials/prospect-prostvac/>, <https://onco.cc/trials/ca184-043-ipilimumab/> .